Tag Archive for: board of directors

Infinitopes Strengthens Board with Two Biotech Leaders to Advance Precision Immunotherapies into the Clinic

/in

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive Directors Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up To support the acceleration of proof-of-concept cancer vaccine, ITOP1, into Phase I/IIa clinical development, to prevent the recurrence of oesophageal cancers Oxford, UK […]

Read more

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans

/in

Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241  The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]

Read more

Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara

/in

Lisa Ferrara, Ph.D., brings over 30 years of experience in orthopaedic medical device innovation and regulatory strategy in the USA Dr Ferrara will play a pivotal role in advancing Renovos’ lead product RENOVITE® BMP-2 through FDA regulatory approval in the USA RENOVITE® is a synthetic, biodegradable nanoclay carrier that is a novel therapeutic delivery platform […]

Read more

Poolbeg Pharma plc – Directorate Change

/in

30 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors. Read more…

Read more

Vicore strengthens its Board of Directors

/in

Stockholm, May 12, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the Annual General Meeting’s election of two very experienced board members, Dr Elisabeth Björk and Dr Michael Buschle. Read more…

Read more